Related Experiment Video
Updated: Aug 14, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users
Poe-Hirr Hsyu1, Jim Lillibridge, Elaine Daniels
1Anadys Pharmaceuticals Inc., San Diego, California 92121, USA. phsyu@anadyspharma.com
Unlabelled:
The effect of nelfinavir 1250 mg twice daily (b.i.d.) on the pharmacokinetics of methadone was determined in 14 HIV-negative methadone users.
Design:
The methadone dose (20-140 mg/day) was stabilized and fixed for at least 1 month before nelfinavir (1250 mg b.i.d. for 8 days) was added to the regimen. The concentrations of methadone enantiomers were measured before and during nelfinavir treatment, and the concentrations of nelfinavir and its active metabolite, AG1402, were measured during nelfinavir treatment. Adverse events and withdrawal/intoxication symptoms were monitored throughout the study.
Results:
Nelfinavir reduced the area under the concentration-time curve of R-methadone, and S-methadone by 43% and 51%, respectively. Nelfinavir and AG1402 concentrations were within the normal range of historical data, and no subject experienced withdrawal symptoms during the study or required dose adjustment during or after the study.
Conclusions:
Although nelfinavir reduced the plasma concentrations of both R- and S-methadone, it seems to have no impact on the maintenance dose of methadone. A routine reduction of methadone dose is not recommended when coadministered with nelfinavir.
More Related Videos
Related Concept Videos
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Pharmacokinetics: Drug–Drug Interactions
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug toxicity: Drug–Drug Interaction
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

